HomeCompareBMXXY vs CL

BMXXY vs CL: Dividend Comparison 2026

BMXXY yields 0.79% · CL yields 2.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BMXXY wins by $2.12M in total portfolio value· pulled ahead in Year 4
10 years
BMXXY
BMXXY
● Live price
0.79%
Share price
$12.44
Annual div
$0.10
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.16M
Annual income
$1,739,853.91
Full BMXXY calculator →
CL
CL
● Live price
2.44%
Share price
$85.23
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.0K
Annual income
$5,451.69
Full CL calculator →

Portfolio growth — BMXXY vs CL

📍 BMXXY pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMXXYCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMXXY + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMXXY pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMXXY
Annual income on $10K today (after 15% tax)
$67.12/yr
After 10yr DRIP, annual income (after tax)
$1,478,875.82/yr
CL
Annual income on $10K today (after 15% tax)
$207.44/yr
After 10yr DRIP, annual income (after tax)
$4,633.94/yr
At 15% tax rate, BMXXY beats the other by $1,474,241.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMXXY + CL for your $10,000?

BMXXY: 50%CL: 50%
100% CL50/50100% BMXXY
Portfolio after 10yr
$1.10M
Annual income
$872,652.80/yr
Blended yield
79.18%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

BMXXY
No analyst data
Altman Z
7.5
Piotroski
7/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+8.5% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMXXY buys
0
CL buys
0
No recent congressional trades found for BMXXY or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMXXYCL
Forward yield0.79%2.44%
Annual dividend / share$0.10$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28.6%
Portfolio after 10y$2.16M$41.0K
Annual income after 10y$1,739,853.91$5,451.69
Total dividends collected$2.11M$18.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: BMXXY vs CL ($10,000, DRIP)

YearBMXXY PortfolioBMXXY Income/yrCL PortfolioCL Income/yrGap
1$10,858$157.93$11,014$313.84$156.00CL
2$11,938$320.51$12,200$415.44$262.00CL
3$13,433$658.71$13,607$553.09$174.00CL
4← crossover$15,759$1,385.36$15,301$741.41+$458.00BMXXY
5$19,899$3,037.77$17,374$1,002.00+$2.5KBMXXY
6$28,462$7,170.10$19,958$1,367.44+$8.5KBMXXY
7$49,624$19,169.19$23,243$1,887.87+$26.4KBMXXY
8$115,567$62,469.69$27,512$2,642.43+$88.1KBMXXY
9$395,588$271,931.01$33,197$3,759.22+$362.4KBMXXY
10$2,163,133$1,739,853.91$40,973$5,451.69+$2.12MBMXXY

BMXXY vs CL: Complete Analysis 2026

BMXXYStock

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Full BMXXY Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this BMXXY vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMXXY vs SCHDBMXXY vs JEPIBMXXY vs OBMXXY vs KOBMXXY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.